AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27606545 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly for 24 weeks
Number of subjects: 373
Study 25740675 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT session (120 min) + web-based CBT homework for 1 month
Number of subjects: 84
Study 23786282 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (Specific Immunotherapy)
Number of subjects: 41
Study 23786282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 21088593 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh
Number of subjects: 20
Study 21088593 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope Video Laryngoscope
Number of subjects: 20
Study 21088593 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview EVO2
Number of subjects: 20
Study 21088593 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 20
Study 21088593 — intervention group
Group type: COMPARATOR
Intervention: Intermediate to difficult comparison
Number of subjects: 20
Study 21088593 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscopic view and time to intubate
Number of subjects: 20
Study 21088593 — intervention group
Group type: COMPARATOR
Intervention: Ease of laryngoscopy (VAS)
Number of subjects: 20
Study 21088593 — intervention group
Group type: COMPARATOR
Intervention: Ease of intubation (VAS)
Number of subjects: 20
Study 21088593 — intervention group
Group type: COMPARATOR
Intervention: Tongue compression score
Number of subjects: 20
Study 21088593 — intervention group
Group type: COMPARATOR
Intervention: Number of attempts
Number of subjects: 20
Study 19144501 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 39
Study 19144501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17219226 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start of OKC quadriceps exercises (P4)
Number of subjects: 68
Study 17219226 — intervention group
Group type: COMPARATOR
Intervention: Late start of OKC quadriceps exercises (P12)
Number of subjects: 68
Study 17219226 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start of OKC quadriceps exercises (H4)
Number of subjects: 68
Study 17219226 — intervention group
Group type: COMPARATOR
Intervention: Late start of OKC quadriceps exercises (H12)
Number of subjects: 68
Study 17219226 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps muscle torques
Number of subjects: 68
Study 17219226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring muscle torques
Number of subjects: 68
Study 15531661 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols
Number of subjects: 84
Study 15531661 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 84
Study 15531661 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plant sterols and exercise
Number of subjects: 84
Study 15531661 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 84
Study 11319935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatigued state
Number of subjects: 37
Study 11319935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued state
Number of subjects: 37
Study 9272403 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 mg once daily
Number of subjects: 48
Study 9272403 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 mg once daily with lorazepam
Number of subjects: 48
Study 7892973 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 46
Study 7892973 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 46
Study 6373039 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg of ivermectin
Number of subjects: 32
Study 6373039 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg of ivermectin
Number of subjects: 32
Study 6373039 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg of ivermectin
Number of subjects: 32
Study 6373039 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/kg of ivermectin
Number of subjects: 32
Study 30597551 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet CBT (iCBT)
Number of subjects: 89
Study 29987442 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based educational intervention conducted over five sessions
Number of subjects: 102
Study 29987442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study 29987442 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based educational intervention
Number of subjects: 102
Study 23665885 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate-heparin lock solution
Number of subjects: 29
Study 23665885 — intervention group
Group type: COMPARATOR
Intervention: Heparin filling
Number of subjects: 29
Study 24502842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic heat pain (46 °C) on the right leg for 7 minutes
Number of subjects: 41
Study 24502842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor pain (1 °C to 4 °C) on the left hand for 5 minutes
Number of subjects: 41
Study 24502842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPT) measured at heterotopic and homotopic locations
Number of subjects: 41
Study 22172428 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold kiwifruit (4 kiwifruit daily)
Number of subjects: 32
Study 22172428 — intervention group
Group type: COMPARATOR
Intervention: Banana (2 bananas daily)
Number of subjects: 32
Study 20420510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (180 microg weekly for 12 weeks)
Number of subjects: 11
Study 17394626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-foam dressing
Number of subjects: 24
Study 17394626 — intervention group
Group type: COMPARATOR
Intervention: Local best practice
Number of subjects: 24
Study 17129441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermic suture
Number of subjects: 200
Study 17129441 — intervention group
Group type: COMPARATOR
Intervention: Para-position suture
Number of subjects: 200
Study 15575122 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program including exercise
Number of subjects: 187
Study 15575122 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 187
Study 10988044 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g taken 30 min before HSG
Number of subjects: 100
Study 10988044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8841797 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1000 mg/day i.m.
Number of subjects: 20
Study 8841797 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) 450 mg/day
Number of subjects: 20
Study 1739153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing information to businesses about the no-smoking law
Number of subjects: 299
Study 1739153 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 299
Study 6715724 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 75 mg
Number of subjects: 18
Study 6715724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 6 mg
Number of subjects: 18
Study 6715724 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen + Chlorpheniramine
Number of subjects: 18
Study 6715724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31791370 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle modification based on traditional Chinese medicine (TCM)
Number of subjects: 56
Study 31791370 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine patient education)
Number of subjects: 56
Study 31791370 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle modification based on TCM
Number of subjects: 56
Study 28417992 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 75 mg
Number of subjects: 2428
Study 28417992 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg
Number of subjects: 2428
Study 28417992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2428
Study 25416193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Number of subjects: 17
Study 25416193 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise
Number of subjects: 17
Study 25416193 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 17
Study 24079823 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture with deep needling at acupuncture points BL33 and BL35
Number of subjects: 500
Study 24079823 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture with non-penetrating needling at sham locations for acupuncture points BL33 and BL35
Number of subjects: 500
Study 24079823 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 500
Study 22197955 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy and high-fat meal
Number of subjects: 3
Study 22197955 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-energy and high-carbohydrate meal
Number of subjects: 3
Study 22197955 — intervention group
Group type: COMPARATOR
Intervention: Fasting (no meal)
Number of subjects: 3
Study 19150590 — intervention group
Group type: EXPERIMENTAL
Intervention: Confrontational counselling with spirometry
Number of subjects: 228
Study 19150590 — intervention group
Group type: COMPARATOR
Intervention: Conventional health education and promotion (control group)
Number of subjects: 228
Study 16718629 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (n = 8)
Number of subjects: 18
Study 16718629 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (n = 10)
Number of subjects: 18
Study 15337695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (2 microg/kg IV bolus followed by an infusion of 0.01 microg/kg per minute)
Number of subjects: 15
Study 15337695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11547716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 205
Study 11547716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 205
Study 11547716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 11547716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 205
Study 11547716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 205
Study 9257066 — intervention group
Group type: EXPERIMENTAL
Intervention: Different radiation doses
Number of subjects: 0
Study 8329252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal administration of midazolam 0.2 mg kg‐1
Number of subjects: 45
Study 8329252 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of midazolam 0.2 mg kg‐1
Number of subjects: 45
Study 8329252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of midazolam 0.2 mg kg‐1
Number of subjects: 45
Study 3518624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (2.1 g/day on a twice‐daily regimen)
Number of subjects: 231
Study 3518624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (1.05 g/day on a twice‐daily regimen)
Number of subjects: 231
Study 3518624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (active medication)
Number of subjects: 231
Study 3518624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 28868637 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assembling peptide P11-4
Number of subjects: 26
Study 27655538 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplement (zinc gluconate granules for 10 days)
Number of subjects: 103
Study 25587218 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group led by a social worker (10 sessions)
Number of subjects: 36
Study 25587218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 21163600 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV TRO-CTA protocol (group 2)
Number of subjects: 60
Study 21163600 — intervention group
Group type: COMPARATOR
Intervention: 120 kV standard protocol (group 1)
Number of subjects: 60
Study 20604703 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cognitive behavior therapy for cigarette smoking cessation
Number of subjects: 301
Study 20604703 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (pretreatment factors, demographic characteristics, treatment assignment)
Number of subjects: 301
Study 20604703 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (Model 1 variables + clinical data during treatment)
Number of subjects: 301
Study 18563952 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0
Study 15954812 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser 60 mJ/2 Hz (G2)
Number of subjects: 48
Study 15954812 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser 80 mJ/2 Hz (G3)
Number of subjects: 48
Study 15954812 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser 100 mJ/2 Hz (G4)
Number of subjects: 48
Study 15954812 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 48
Study 12038906 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9691858 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.03 mg kg‐1 i.v.
Number of subjects: 28
Study 9691858 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.06 mg kg‐1 i.v.
Number of subjects: 28
Study 7661381 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-rich spa gas
Number of subjects: 10
Study 7661381 — intervention group
Group type: COMPARATOR
Intervention: Water-vapor-saturated air
Number of subjects: 10
Study 2475322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 mg/kg)
Number of subjects: 24
Study 791434 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHD) for irrigation of vas
Number of subjects: 61
Study 791434 — intervention group
Group type: COMPARATOR
Intervention: Sterile water for irrigation of vas
Number of subjects: 61
Study 791434 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigated group
Number of subjects: 61
Study 791434 — intervention group
Group type: COMPARATOR
Intervention: Water for irrigation of vas
Number of subjects: 61
Study 791434 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue uptake test
Number of subjects: 61
Study 28100629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronocort (modified-release hydrocortisone)
Number of subjects: 18
Study 25385878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler device (0.22 mg, 0.45 mg, 0.67 mg doses)
Number of subjects: 36
Study 25385878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler device (0.67 mg repeated hourly for 12 hr)
Number of subjects: 36
Study 25385878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler device
Number of subjects: 36
Study 23490435 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and protein ingestion at rest (RGP)
Number of subjects: 21
Study 23490435 — intervention group
Group type: COMPARATOR
Intervention: Glucose ingestion at rest (RG)
Number of subjects: 21
Study 23490435 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and protein ingestion after exercise (EGP)
Number of subjects: 21
Study 23490435 — intervention group
Group type: COMPARATOR
Intervention: Glucose ingestion after exercise (EG)
Number of subjects: 21
Study 21670283 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt to write down just a date
Number of subjects: 0
Study 21670283 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt to write down both a date and a time
Number of subjects: 0
Study 21670283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prompt)
Number of subjects: 0
Study 19487269 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 or 100 mg every 2 or 4 weeks + MTX
Number of subjects: 171
Study 19487269 — intervention group
Group type: COMPARATOR
Intervention: MTX alone (placebo + MTX)
Number of subjects: 171
Study 19487269 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 171
Study 16688035 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARITE Artificial Disc (TDR)
Number of subjects: 688
Study 16688035 — intervention group
Group type: COMPARATOR
Intervention: ALIF with threaded fusion cages and autograft (Control)
Number of subjects: 688
Study 14769595 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine tartrate
Number of subjects: 20
Study 14769595 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride
Number of subjects: 20
Study 14769595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of brimonidine and dorzolamide
Number of subjects: 20
Study 14769595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11732521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 120
Study 11732521 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120
Study 11732521 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study 8922654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 22
Study 1425726 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 337
Study 1425726 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime/gentamicin (plus metronidazole for suspected anaerobe infection)
Number of subjects: 337
Study 1425726 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime/gentamicin
Number of subjects: 337
Study 3907843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg OD
Number of subjects: 12
Study 3907843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg OD
Number of subjects: 12
Study 3907843 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg BID
Number of subjects: 12
Study 30001703 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive STEPS intervention (two-way daily text messaging as a reminder system, progressing to in-person counseling if needed)
Number of subjects: 0
Study 30001703 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 28956786 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide added to insulin for 26 weeks
Number of subjects: 71
Study 28956786 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 71
Study 28956786 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide added to insulin for 8 weeks
Number of subjects: 71
Study 24165860 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity adoption via motivational interviewing
Number of subjects: 184
Study 24165860 — intervention group
Group type: COMPARATOR
Intervention: Physical activity adoption via education
Number of subjects: 184
Study 24490058 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (1.33 grams taken with 236.6 mL of water before meals)
Number of subjects: 53
Study 24490058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically looking capsules taken with 236.6 mL of water before meals)
Number of subjects: 53
Study 24490058 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan
Number of subjects: 53
Study 24490058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 24490058 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan and Placebo
Number of subjects: 53
Study 21996369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate, n = 197
Number of subjects: 555
Study 21996369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methotrexate (HDM), n = 79
Number of subjects: 555
Study 21996369 — intervention group
Group type: COMPARATOR
Intervention: All patient groups (n = 555)
Number of subjects: 555
Study 18281791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency radiosurgery
Number of subjects: 60
Study 18281791 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 60
Study 16990385 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC
Number of subjects: 75
Study 16990385 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC
Number of subjects: 75
Study 16990385 — intervention group
Group type: COMPARATOR
Intervention: No infusion
Number of subjects: 75
Study 14680337 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-combined estrogen plus progestin
Number of subjects: 0
Study 14680337 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone (ongoing trial)
Number of subjects: 0
Study 11059442 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant therapy (including tricyclic antidepressants such as amitriptyline, clomipramine, desipramine, doxepin, trimipramine, and the antiserotonin agent mianserin)
Number of subjects: 12
Study 11059442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8809640 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic G-CSF
Number of subjects: 606
Study 8809640 — intervention group
Group type: COMPARATOR
Intervention: Control (no G-CSF)
Number of subjects: 606
Study 1736695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac 75 mg loading dose followed by 5 mg/hour infusion
Number of subjects: 40
Study 1736695 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 1736695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac
Number of subjects: 40
Study 6744777 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem with digoxin
Number of subjects: 24
Study 3963154 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and glycopyrrolate
Number of subjects: 30
Study 3963154 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and scopolamine
Number of subjects: 30
Study 3963154 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 30